Title : Design and Development of Long acting Formulation for the Treatment of Posterior Segment Eye Diseases

Type of Material: Thesis
Title: Design and Development of Long acting Formulation for the Treatment of Posterior Segment Eye Diseases
Researcher: Garkal, Atul
Guide: Mehta, Tejal
Department: Institute of Pharmacy
Publisher: Nirma University, Ahmedabad
Place: Ahmedabad
Year: 2023
Language: English
Subject: Age-related macular degeneration
Anti-VEGF
Clinical Pre Clinical and Health
Pharmacology and Pharmacy
Pharmacology and Toxicology
Pharmacy
Medical Sciences
Medical and Health Sciences
Dissertation/Thesis Note: PhD; Institute of Pharmacy, Nirma University, Ahmedabad, Ahmedabad; 2023
Fulltext: Shodhganga

00000000ntm a2200000ua 4500
001456589
003IN-AhILN
0052024-10-11 12:14:56
008__241011t2023||||ii#||||g|m||||||||||eng||
035__|a(IN-AhILN)th_456589
040__|dIN-AhILN|aNIRU_382481
041__|aeng
100__|eResearcher|aGarkal, Atul
110__|aInstitute of Pharmacy|0U-0146|dAhmedabad|bNirma University, Ahmedabad|ein
245__|aDesign and Development of Long acting Formulation for the Treatment of Posterior Segment Eye Diseases
260__|aAhmedabad|c2023|bNirma University, Ahmedabad
300__|dDVD
502__|d2023|bPhD|cInstitute of Pharmacy, Nirma University, Ahmedabad, Ahmedabad
518__|d2023|oDate of Award
518__|d2019|oDate of Registration
520__|aAge-related macular degeneration (AMD) is a chronic eye ailment characterized by gradual loss of central vision. Currently, intravitreal injections of anti-VEGF agents are used to manage AMD. However, these injections only halt the progression of the disease. Furthermore, the currently available anti-VEGF agents in the market exhibit a short half-life and hence require frequent administration. Sustained delivery of anti-VEGF agents remains a challenge to deliver across anatomic locations. Innovations in nanotechnology, implantable devices, and formulation strategies hold promise for overcoming these challenges and improving the efficacy of anti-VEGF agents. Polymeric implants with high drug loading capacity can provide sustained delivery of anti-VEGF agents without any complications. Thus, in the present study, an attempt has been made to develop a technique for fabricating cylindrical biodegradable implants which can deliver anti-VEGF agents over 12 months. Small molecule i.e. carotenoid based implants was
650__|aPharmacy|2UGC
650__|aMedical Sciences|2UGC
650__|aMedical and Health Sciences|2AIU
653__|aAge-related macular degeneration
653__|aAnti-VEGF
653__|aClinical Pre Clinical and Health
653__|aPharmacology and Pharmacy
653__|aPharmacology and Toxicology
700__|aMehta, Tejal|eGuide
856__|uhttp://shodhganga.inflibnet.ac.in/handle/10603/536130|yShodhganga
905__|afromsg

User Feedback Comes Under This section.